

# ALLERGOLOGY

GENERAL PRINCIPLES: LECTURE 1

# Allergy definition

- ▣ Type of hypersensitivity reactions of the immune system.
- ▣ may involve more than one type of reaction.





# Important factors

- **Host factors;** heredity, gender, race, and age.
- **Environmental factor;** infectious diseases during early childhood, environmental pollution, allergen levels and dietary changes.
- Site specific factors (peculiarities of the local receptors)

## Gel and Coombs classification of hypersensitivities

- ▣ **Type I** -immediate hypersensitivity - IgE-mediated.
- ▣ **Type II** - antibody-dependent cytotoxic hypersensitivity ( with participation of natural killer cells, eosinophils, macrophages), complement
- ▣ **Type III** - immune complex disease) - circulating antigen-antibody immune complexes deposited in vessels or tissue
- ▣ **Type IV** - delayed hypersensitivity - T-cell-mediated;

# Gel and Coombs classification of hypersensitivities.

 <p><b>Type I</b></p>	 <p><b>Type II</b></p>	 <p><b>Type III</b></p>	 <p><b>Type IV</b></p>
<p>IgE-Mediated Hypersensitivity</p>	<p>IgG-Mediated Cytotoxic Hypersensitivity</p>	<p>Immune Complex-Mediated Hypersensitivity</p>	<p>Cell-Mediated Hypersensitivity</p>
<p>Ag induces crosslinking of IgE bound to mast cells and basophils with release of vasoactive mediators</p>	<p>Ab directed against cell surface antigens mediates cell destruction via complement activation or ADCC</p>	<p>Ag-Ab complexes deposited in various tissues induce complement activation and an ensuing inflammatory response mediated by massive infiltration of neutrophils</p>	<p>Sensitized T<sub>H</sub> cells release cytokines that activate macrophages or T<sub>C</sub> cells which mediate direct cellular damage</p>
<p>Typical manifestations include systemic anaphylaxis and localized anaphylaxis such as hay fever, asthma, hives, food allergies, and eczema</p>	<p>Typical manifestations include blood transfusion reactions, erythroblastosis fetalis, and autoimmune hemolytic anemia</p>	<p>Typical manifestations include localized Arthus reaction and generalized reactions such as serum sickness, necrotizing vasculitis, glomerulonephritis, rheumatoid arthritis, and systemic lupus erythematosus</p>	<p>Typical manifestations include contact dermatitis, tubercular lesions and graft rejection</p>

# Sell et al. classification

- ▣ Inactivation/activation antibody reactions
- ▣ Cytotoxic or cytolytic antibody reactions
- ▣ Immune-complex reactions
- ▣ Allergic reactions
- ▣ T-cell cytotoxic reactions
- ▣ Delayed hypersensitivity reactions
- ▣ Granulomatous reactions

Immediate Hypersensitivity Reactions

Updated: Feb 09, 2015


Author: Becky Buelow, MD, MS; Chief Editor: Michael A Kaliner, MD more...

<https://emedicine.medscape.com/article/136217-overview>

# Pathogenesis

- ▣ Allergen processing and presenting peptides from allergens on MHCII class: dendritic cells in mucosal surface
- ▣ MHC class II molecule+antigen complex: ligand of T-cell receptors on Naive CD4<sup>+</sup> T cells
- ▣ Naive CD4<sup>+</sup> T cells differentiation to allergen-specific Th2 cell
- ▣ Th2 cells: cytokines, promoting isotype switching of B cells to produce specific IgE and proliferation of eosinophils, mast cells and neutrophils
- ▣ Produced antigen-specific IgE binds to high-affinity IgE receptors on mast cells or basophils.







# Type I

- Antigen binds to IgE bound to tissue mast cells and blood basophils
- release of preformed mediators (histamine, proteases, chemotactic factors)
- synthesis of other mediators (prostaglandins, leukotrienes, platelet-activating factor, cytokines).
- mediators cause vasodilation, increased capillary permeability, mucus hypersecretion, smooth muscle spasm, and tissue infiltration with eosinophils, type 2 helper T ( $T_H2$ ) cells, and other inflammatory cells.
- atopic disorders (allergic asthma, rhinitis, conjunctivitis), anaphylaxis, some cases of angioedema, urticaria, and latex and some food allergies. Type I reactions develop < 1 h after exposure to antigen.

# Main mediators: Pre-existing

- ▣ Histamine (H1, H2 receptors): smooth muscles contraction in airways and GI, vasodilation and leakage (incl.skin), increased mucus production, itching
  - ▣ Trypsase: released by mast cells; cleave C3, C3a, airways remodeling
  - ▣ Proteoglycans: inclheparin and chondroitin sulfate
  - ▣ Chemotactic factors:
    - eosinophilic chemotactic factor of anaphylaxis - Eos chemotaxis
    - inflammatory factor of anaphylaxis - neutrophil chemotaxis
    - major basic protein (released by Eos)
- THIUS - tissue damage in the later phases of allergic reactions.

# Main mediators: newly synthesized

- Leucotriens: B4 (Neutrophils, vessels permeability); C4, D4 – bronchoconstriction, vessels permeability, arteriolar constriction; E4 bronchial responsiveness; vascular permeability
- Prostaglandins: bronchoconstriction, peripheral vasodilation, coronary vasoconstriction; D2 also pulmonary artery constriction, increase of histamine release
- Thromboxane A2 – broncho- and vasoconstriction, platelet aggregation
- Platelet-activating factor (PAF): bronchoconstriction, increases vascular permeability, causes, eosinophils and neutrophils chemotaxis and degranulation
- Adenosine: bronchoconstrictor, potentiates IgE-induced mast cell mediator release.
- Cytokines: IL-4 (maintains TH2 cell proliferation, B cells switch to IgE synthesis); IL-5 - maturation, chemotaxis, activation, and survival of eosinophils. primes basophils for histamine and leukotriene release; IL-6 (mucus production) IL-13 (same effects as IL-4)

# Type II

## **antibody-dependent cytotoxic hypersensitivity**

- antibody binds to cell surface antigens or to a molecule coupled to a cell surface.
- antigen-antibody complex activates cells that participate in antibody-dependent cell-mediated cytotoxicity (natural killer cells, eosinophils, macrophages), complement, or both.
- hyperacute graft rejection of an organ transplant, Coombs-positive hemolytic anemias, Hashimoto thyroiditis, and anti-glomerular basement membrane disease (eg, Goodpasture syndrome)

# Type III reactions (immune complex disease)

- circulating antigen-antibody immune complexes deposited in vessels or tissue.
- activate the complement system or bind to and activate certain immune cells, resulting in release of inflammatory mediators.
- immune complexes deposit in various tissues (glomeruli, blood vessels)
- isotype of induced antibodies changes, and glycosylation, size, and charge of the complex's components contribute to the clinical response.
- serum sickness, SLE, RA, leukocytoclastic vasculitis, cryoglobulinemia, hypersensitivity pneumonitis, and several types of glomerulonephritis.
- develop 4 to 10 days after exposure to antigen and, if exposure to the antigen continues, can become chronic.

# Type IV reactions (delayed hypersensitivity)

- T cells, sensitized after contact with a specific antigen, are activated by reexposure to the antigen
- tissue damage by direct toxic effects/cytokines release
- Activation of eosinophils, monocytes and macrophages, neutrophils, or natural killer cells.
- contact dermatitis (poison ivy), hypersensitivity pneumonitis, allograft rejection, immune response to TB, and many forms of drug hypersensitivity.

# Type I: Atopic and Allergic Disorders

- ▣ **Allergy:** is any abnormal immune response to a foreign antigen regardless of mechanism.
- ▣ **Atopy:** IgE-mediated abnormal immune response; all atopic disorders are type I hypersensitivity disorders.



# Spectrum of atopic diseases

- ▣ Nose - allergic rhinitis
- ▣ Eyes - allergic conjunctivitis
- ▣ Skin: extrinsic atopic dermatitis, immune-mediated urticaria, immune-mediated angioedema, acute latex allergy
- ▣ Bronchi and lungs: (some cases of asthma, IgE-mediated components of allergic bronchopulmonary aspergillosis)
- ▣ allergic reactions to venomous stings
- ▣ Systemic: anaphylaxy, hay fever

# Latex Sensitivity

- ▣ Abnormal immune response to water-soluble proteins in latex products (rubber gloves, dental dams, condoms, tubing for respiratory equipment, catheters, enema tips with inflatable latex cuffs)
- ▣ acute (IgE-mediated)/delayed (cell-mediated).
- ▣ Acute: urticaria, anaphylaxis
- ▣ Delayed: dermatitis.
- ▣ Skin may be irritated and crusted - not allergy, usually chemical irritation
- ▣ Diagnosis: history; assays for detecting IgE antil latex antibodies are available; skin testing is available in Europe and Canada, but not routinely in the US.
- ▣ Treatment: avoidance of latex, latex-free gloves

# Etiology: multifactorial

- ▣ Environment
- ▣ Genetic
- ▣ Site specific

# Genetic:

- ▣ familial inheritance
- ▣ association between atopy and HLA loci (peptides promoting Th2 response).
- ▣ polymorphisms of genes: for the high-affinity IgE receptor  $\beta$ -chain, IL-4 receptor  $\alpha$ -chain, IL-4, IL-13, CD14, dipeptidyl-peptidase 10 (DPP10), and a disintegrin and metalloprotease domain 33 ( *ADAM33* ).

# Environmental factors:

## Allergens

- ▣ Proteins: serum, vaccines
- ▣ Pollen: rye grass, timothy grass, birch trees, ragweed and lots...
- ▣ Food: nuts, seafood, eggs, peas, beans, citrus, apples (not green), honey, milk, chocolate, grapes, peaches, nuts, tomatoes...
- ▣ Epidermal: epidermis of cats, dogs, horses etc
- ▣ Drugs: penicillin, sulfonamides etc (adverse reactions are not allergy), sometimes even glucocorticosteroids
- ▣ Insect products (bee, wasp, ant venoms, cocroach calyx, house dust mites etc)
- ▣ Mold spores


# Environmental factors and Th2 response

- Environmental factors interact with genetic ones to maintain type 2 helper T ( $T_H2$ ) response
- $T_H2$  cells activate eosinophils, promote IgE production, and are proallergic
- Late exposure to indoor and outdoor environmental factors in infants
- chronic allergen exposure and sensitization
- Diet
- environmental pollutants.

# Late exposure to indoor and outdoor environmental factors in infants

- early childhood exposure to bacterial and viral infections and endotoxins (lipopolysaccharide etc) shifts  $T_H2$ -cell responses to  $T_H1$ -cell responses and suppression of  $T_H2$  mediated reactions.
- This is mediated by regulatory T (CD4+CD25+Foxp3+;  $T_{reg}$ ) cells (capable of suppressing  $T_H2$ -cell responses) and IL-12-secreting dendritic cells (drive  $T_H1$ -cell responses)
- Trends to smaller families, fewer children, cleaner indoor environments, early use of antibiotics may limit children's exposure to the infectious agents/ decrease shift to predominantly  $T_H1$ -cell response
- Because of this - increased prevalence of some allergic disorders.






# Site-specific factors

- ▣ adhesion molecules in bronchial epithelium/skin
- ▣ molecules in the GI tract that direct  $T_H2$  cells to target tissues.


# Pathophysiology

- Mast cells are widely distributed but are most concentrated in skin, lungs, and GI mucosa
- Allergen + IgE-sensitized mast cells/ basophils
- Histamine release from intracellular granules

**(a) Induction phase**



**(b) Effector phase**



Key:




Goblet cell

Receptors that might lead to

- (i) reduced levels of cAMP and smooth muscle cell contraction
- (ii) mucus hyperproduction by goblet cells

*TRENDS in Immunology*

## Phases of allergic reaction (on example of atopic asthma)



# Immediate Hypersensitivity Reactions

Updated: Feb 09, 2015

Author: Becky Buelow, MD, MS; Chief Editor: Michael A Kaliner, MD more...

<https://emedicine.medscape.com/article/136217-overview>



# Other than histamin mediators pre-formed in mast cells granules

- ▣ Cytokines TNF- $\alpha$ , IL-1, IL-6.
- ▣ Chemoattractants for Neutrophils and Eosinophils.
- ▣ Enzymes
  - tryptase, chymase, cathepsin.
  - Changes in connective tissue matrix, tissue breakdown.
- ▣ Leukotrienes
- ▣ Prostaglandins
- ▣ Th2 cytokines- IL-4, IL-5, IL-13, GM-CSF



# Histamine effects

- ▣ Local vasodilation (causing erythema)
- ▣ Increased capillary permeability and edema (producing a wheal)
- ▣ Vasodilation of surrounding arterioles mediated by neuronal reflex mechanisms (causing flare – the redness around a wheal)
- ▣ Stimulation of sensory nerves (causing itching)
- ▣ Smooth muscle contraction in the airways (bronchoconstriction) and in the GI tract (increasing GI motility)
- ▣ Increased nasal, salivary, and bronchial gland secretions



# Frequent histamine release:

- ▣ potent arteriolar dilator
- ▣ causes extensive peripheral pooling of blood and hypotension
- ▣ cerebral vasodilation - factor in vascular headache.
- ▣ loss of plasma and plasma proteins from the vascular space which worsens circulatory shock.
- ▣ this loss triggers a compensatory catecholamine response

# Non-specific/non-allergic histamin liberation

- ▣ physical disruption of tissue and various substances (tissue irritants, opiates, surface-active agents, complement components C3a and C5a) can trigger histamine release directly, independent of IgE
- ▣ This causes pseudoallergic symptoms

# Continuation of sensitization cycle

## Eosinophils

- Eosinophils play key role in late phase reaction.
- Eosinophils make
  - enzymes,
  - cytokines (IL-3, IL-5, GM-CSF),
  - Lipid mediators (LTC<sub>4</sub>, LTD<sub>4</sub>, PAF)
- Eosinophils can provide CD40L and IL-4 for B cell activation.

# Types of allergens

- ▣ Pollen
- ▣ Dust
- ▣ Epidermal
- ▣ Food
- ▣ Drugs
- ▣ Insect – venom, cocroaches etc
- ▣ Latex

# Pollen Canada (shortened)

Tree pollen	Grass pollen	Weed pollen	Mould spores
<b>British Columbia (Coastal)</b>	<ul style="list-style-type: none"> <li>• Season: early February to mid-July</li> <li>• Primarily deciduous trees (alder, birch, poplar, elm, oak)</li> </ul>	<ul style="list-style-type: none"> <li>• Season: end of April to September</li> <li>• Highest grass concentrations: early June to mid-July</li> </ul>	<ul style="list-style-type: none"> <li>• Not usually a major factor; no native ragweed</li> </ul>
<b>British Columbia (Interior)</b>	<ul style="list-style-type: none"> <li>• Season: late March to mid-July</li> <li>• Primarily deciduous trees (willow, birch, poplar)</li> </ul>	<ul style="list-style-type: none"> <li>• Season starts in early May in southern parts of the province; starts up to 1 month later in northern parts</li> </ul>	<ul style="list-style-type: none"> <li>• Ragweed is minimal</li> </ul>

Moote, W., Kim, H. Allergen-specific immunotherapy. *All Asth Clin Immun* 7, S5 (2011).  
<https://doi.org/10.1186/1710-1492-7-S1-S5>

# Common symptoms

- upper respiratory tract: rhinorrhea, sneezing, and nasal congestion, itching, nasal turbinate edema, sinus pain during palpation
- lower respiratory tract: wheezing, dyspnea, stridor (in severe cases)
- Skin: itching, urticaria, angioedema, dermatitis, and skin lichenification
- Eyes: itching, conjunctival hyperemia and edema.
- Systemic: fever (hay fever), hypotension and shock (in anaphylaxis)

# Diagnosis

- ▣ Clinical evaluation
- ▣ CBC
- ▣ serum IgE levels
- ▣ skin testing and allergen-specific serum IgE testing (specific tests)
- ▣ Rarely provocative testing



# Clinical evaluation

- ▣ frequency and duration of attacks and changes over time
- ▣ Identification of triggering factors
- ▣ Relation to seasonal or situational settings (predictably occurring during pollen seasons; after exposure to animals, hay, or dust; during exercise; or in particular places)
- ▣ Family history of similar symptoms or of atopic disorders
- ▣ Responses to attempted treatments
- ▣ Age at onset: childhood asthma is likely to be atopic and asthma beginning after age 30 is not.
- ▣ Professional anamnesis: latex products, other allergens

# Allergologic anamnesis

- ▣ 1. Allergic diseases in case history: asthma, pollinosis, urticaria, quincjedema, migraine, exema, allertic rhinitis, allergic dermattis etc, other allertic skin diseases, drug allergy, serim diseases (date and manifestations)
- ▣ 2. Allergic diseases in relatives in past and nowadays
  - a) father/relatives
  - ▣ б) mother/relatives
  - ▣ г) children
- ▣ 4. Serum reaction and vaccination reaction (what/when)

- ▣ 5. Drug reaction (what/when) ; anaphylactic shock, urticaria, quikedema, bronchospasm, dermatites of different types, itching, allergic rhinitis, conqunctivitis (dates, type of reaction)
- ▣ 5.1. antibiotics: pelicillines
- ▣ Aminoglycosides
- ▣ Streptomycine
- ▣ Sintomycine, levomycetine
- ▣ Other antibiotics
- ▣ 5.2. sulfonamides
- ▣ 5.4. local anesthetics
- ▣ 5.5. iodine containing drugs
- ▣ 5.6. B group vitamines
- ▣ 5.7. other drugs
- ▣ 5.8.other side reactions: dizziness, nausea, fever, vomiting, disbiosis etc (with data)

- ▣ 6. seasonal exacerbations (summer, autumn, winter, spring)
- 7. climate influence on the disease course
- ▣ 8. weather and physical factors influence (cold, heating)
- ▣ 9. physical exercise, negative emotions etc
- ▣ 10. relation to respiratory infections (viral infections, bronchitis, tonsillitis, pneumonia)
- ▣ 11. relation to menstrual cycle, feeding, pregnancy, delivery

- ▣ 12. where is worse – at home, at the working place, in the street, in the forest, at the day or night
- ▣ 13. influence of food, drinks, alcohol, cosmetic, antiinsects, dust, smells, animals, clothes, bad settings
- ▣ 14. situation at home (material of which the home is built, warming, is there a wet surroundings, carpets, furniture, books, bed settings, animals, fishes)
- ▣ 15. working conditions and their changes during the life

# Non-specific tests

- CBC: eosinophilia (except patients taking corticosteroids); normal eosinophil count does not exclude allergy. Total WBC is usually normal.
- Anemia and thrombocytosis - not typical, indicate systemic inflammatory disorder.
- Conjunctival / nasal secretions / sputum: WBC, formula (eosinophilia suggests probability of  $T_H2$ -response)
- **Serum IgE levels:** elevated (also in parasitic infections, infectious mononucleosis, autoimmune disorders, drug reactions, hyper-IgE syndrome, Wiskott-Aldrich syndrome, some forms of multiple myeloma).

# Specific tests:

- ▣ Allergen-specific serum IgE tests: enzyme-labeled anti-IgE antibody
- ▣ Performed when skin testing might be ineffective or risky or in case of skin diseases (eczema/psoriasis) which make skin testing difficult
- ▣ allergen is immobilized on a synthetic surface, substrate for the enzyme is then added; the substrate provides colorimetric fluorescent or chemiluminescent detection of binding.

# Skin tests

- ▣ standardized concentrations of antigen introduced directly into skin
- ▣ higher positive predictive values for diagnosing allergic rhinitis and conjunctivitis than for diagnosing allergic asthma or food allergy; negative predictive value for food allergy is high.
- ▣ most commonly used antigens are pollens (tree, grass, weed), molds, house dust mites, animal danders and sera, insect venom, foods, and  $\beta$ -lactam antibiotics.



# Two skin test techniques can be used:

- ▣ Percutaneous (prick)
- ▣ Intradermal

# Percutaneous (prick):

- ▣ drop of antigen extract is placed on the skin
- ▣ skin is tented up and pricked or punctured
- ▣ through the extract with the tip of a 27-gauge needle held at a 20° angle or with a commercially available prick device.

# Intradermal

- ▣ more sensitive
- ▣ less specific
- ▣ can be used to evaluate sensitivity to allergens when prick test results are negative or equivocal:
- ▣ typically 0.02 mL is injected intradermally with a 0.5- or 1-mL syringe and a 27-gauge short-bevel needle.

# Necessary for both

- ▣ Negative control: diluent
- ▣ Positive control - histamine (10 mg/mL for prick tests, 0.01 mL of a 1:1000 solution for intradermal tests)
- ▣ For patients who have had a recent (< 1 yr) generalized reaction to the test antigen
- ▣ testing begins with the standard reagent diluted 100-fold
- ▣ then 10-fold
- ▣ then the standard concentration.

- ▣ Drugs which can interfere with results and should be stopped a few days to a week before testing:
- ▣ Antihistamines
- ▣ tricyclic antidepressants,
- ▣ monoamine oxidase inhibitors;
- ▣ some recommendations insist on cessation of  $\beta$ -blockers because these patients are more likely to have risk factors for severe reactions.

# Positive test results

- ▣ Diluent – negative
- ▣ Histamin - positive
- ▣ Causative allergen: positive
  
- ▣ Positive means
- ▣ wheal and flare reaction
- ▣ wheal diameter is 3 to 5 mm more than that of the negative control after 15 to 20 min.

# Negative test result

- ▣ Diluent – negative
- ▣ Histamin - positive
- ▣ Causative allergen: negative
  
- ▣ Skin reacts on histamin normally, but allergens don't cause the reaction

# False positive

Diluent – positive

Histamine – positive

Allergen - positive

Cause may be dermatographism (a wheal and flare reaction provoked by stroking or scraping the skin).



# False negative

Diluent – negative

Histamine – negative

Allergen - negative

If used from one kit

Cause - allergen extracts have been stored incorrectly or are outdated.

# False negative-2

- ▣ Histamine is positive, allergens are negative, but there is strong evidence of allergy
- ▣ histamine sample is still active or histamine is used from another kit, histamine reaction may be positive
- ▣ Patient may not react on commercial variant of allergens (some common house dust, common cat's or dog's epidermis), but may react on the allergens from his own environment
- ▣ In case if this is suspected, individual allergens should be performed

# Individual allergens

- ▣ Concrete house dust taken from patients home
- ▣ Epidermis of the concrete cat, dog etc
- ▣ .....
  
- ▣ In cases when the anamnestic signs are present, but tests give negative results



# Other specific tests

- ▣ **Provocative testing** : exposure of the mucosae to allergen and is indicated for patients who must document their reaction (for occupational or disability claims) , sometimes for diagnosis of food allergy, cold-induced urticaria etc
- ▣ **Ophthalmic testing**: no advantage over skin testing and is rarely used.
- ▣ **Nasal and bronchial challenge**: primarily research, but bronchial challenge is sometimes used when the clinical significance of a positive skin test is unclear or when no antigen extracts are available (for occupation-related asthma)

# Treatment

- ▣ Removal or avoidance of allergic triggers
- ▣ H<sub>1</sub> blockers
- ▣ Mast cell stabilizers
- ▣ Anti-inflammatory corticosteroids and leukotriene inhibitors
- ▣ Immunotherapy (desensitization)

# H1 blockers

Drug	Usual Adult Dosage	Available Preparations
Sedating		
Brompheniramine	4 mg q 4–6 h or 8 mg q 8–12 h	4-, 8-, and 12-mg tablets 2 mg/5 mL elixir 8- and 12-mg tablets (sustained-release)
Chlorpheniramine	2–4 mg q 4–6 h	2-mg chewable tablets 4-, 8-, and 12-mg tablets 2 mg/5 mL syrup 8-/12-mg tablets/ capsules (timed-release)
Clemastine	1.34 mg (1.0 mg of base) bid to 2.68 mg tid	1.34- and 2.68-mg tablets 0.67 mg/5 mL syrup
Cyproheptadine	4 mg tid or qid (maximum 0.5 mg/kg/day)	4-mg tablets <sup>†</sup> 2 mg/5 mL syrup
Dexchlorpheniramine	2 mg q 4–6 h	2-mg tablets 2 mg/5 mL syrup 4- and 6-mg tablets (extended-release)
Diphenhydramine	25–50 mg q 4–6 h	25- and 50-mg capsules or tablets 12.5 mg/mL syrup 12.5 mg/5 mL elixir
Hydroxyzine	25–50 mg tid or qid	25-, 50-, 100-mg capsules 10-, 25-, 50-, and 100-mg tablets 10 mg/5 mL syrup 25 mg/5 mL oral susp.

## Nonsedating

Acrivastine/pseudoephedrine	8/60 mg bid or tid	8-mg acrivastine plus 60-mg pseudoephedrine capsules
Cetirizine	5–10 mg once/day	5- and 10-mg tablets 1 mg/mL syrup
Desloratadine	5 mg once/day	5-mg tablets 0.5 mg/mL syrup
Fexofenadine	60 mg bid or 180 mg once/day	30-, 60-, and 180-mg tablets 6 mg/mL oral suspension
Levocetirizine	5 mg once/day	5-mg tablets 0.5 mg/mL oral suspension
Loratadine	10 mg once/day	10-mg tablets 1 mg/mL syrup
Mizolastine	10 mg once/day	10-mg tablets



# Attention!

- ▣ All sedating antihistamines have strong anticholinergic properties.
- ▣ they should not be used in the elderly or in patients with glaucoma, benign prostatic hyperplasia, constipation, delirium, dementia, or orthostatic hypotension.
- ▣ Commonly cause dry mouth, blurred vision, urinary retention, constipation, and orthostatic hypotension.

# Specific immune therapy

- ▣ Performed in remission only
- ▣ In period without allergens exposure (not in pollen exposure season)
- ▣ Allergens used are those which typically cannot be avoided: pollens, house dust mites, molds, and venom of stinging insects.
- ▣ Individual allergens can be made (dust allergen in patient's home, epidermis of patient's pet)

# Indications

- ▣ allergic rhinitis, conjunctivitis, hay fever, atopic asthma of mild course of the disease (all with high IgE); stinging insect (venom) hypersensitivity
- ▣ Asthma should be controlled, FEV1 > 70% of predicted
- ▣ Atopic dermatitis of mild and moderate course with high degree of sensibilization
- ▣ The best results are to house dust mites (2++)
- ▣ Also performed if contact with home pet can't be avoided

# Contraindications:

- ▣ 3-5 step of asthma treatment (moderate/severe course)
- ▣ Non Th2-variant (non-atopic, low IgE)
- ▣ Current use of glucocorticosteroids (suppress immune reactions)
- ▣ Beta-blockers are relative contraindications in venoms hypersensitivity
- ▣ Significant comorbidities (cardiovascular etc)
- ▣ Anaphylactic shock in case history


# Special considerations:

- • Children < 6 yrs
- Pregnancy
- Elderly
- Malignancy, immunodeficiency and autoimmune diseases (mentioned in some articles, but autoimmune patients usually have glucocorticosteroid treatment which is absolute contraindication); immunodeficiency – depend on nosological units (there are IgE-elevated variants)

# Principle

- ▣ induction of IgG antibodies
- ▣ IgGs compete with IgE for allergen or block IgE from binding with mast cell IgE receptors
- ▣ induction of interferon  $\gamma$ , IL-12, and cytokines secreted by  $T_H1$  cells; or induction of regulatory T cells
- ▣ In total – switch from Th2 to Th1 response
- ▣ Performed by allergen injection in gradually increasing doses (hyposensitization or desensitization)

# Principle: Th2 to Th1 switch



# Classification

- ▣ Preseasonal
- ▣ Preseasonal-seasonal
- ▣ Whole year



# Principle

- ▣ injections are given monthly.
- ▣ Dose: start dose from 0.1 to 1.0 biologically active units (BAU), depending on initial sensitivity
- ▣ weekly or biweekly 2 times increase
- ▣ Until maximum tolerated dose (start of moderate adverse effects)
- ▣ maximum tolerated dose is given every 4 to 6 wks year-round

# Build-up (induction) phase

- ▣ weekly injections
- ▣ starting with a very low dose,
- ▣ gradual increases in dose over the course of 3–6 months


# **maintenance phase**

- ▣ every 4–6 weeks for venom and every 4 weeks for inhalant allergens
- ▣ period of 3–5 years.

# Principle

- ▣ Observation of patients 30 min postinjection (risk of anaphylaxy)
- ▣ Appearance of blood during injection is the protocol violation; the patients are at high risk for anaphylaxy and should be observed more closely

# Specific immune therapy in allergic rhinitis



Moote, W., Kim, H. Allergen-specific immunotherapy. *All Asth Clin Immun* 7, S5 (2011).  
<https://doi.org/10.1186/1710-1492-7-S1-S5>

# Sublingual immunotherapy

- ▣ placing a tablet of allergen extract under the tongue until it is dissolved
- ▣ available for the treatment of grass and ragweed allergy, as well as house dust mite-induced allergic rhinitis (with or without conjunctivitis).
- ▣ Tablets: Oralair<sup>®</sup>, Grastek<sup>®</sup>, Ragwitek<sup>®</sup> Acarizax<sup>™</sup>
- ▣ (see Table [3](#)) [[23](#)–[26](#)]. The sublingual route of immunotherapy offers multiple potential benefits over the subcutaneous route including the comfort of avoiding injections, the convenience of home administration, and a favourable safety profile. Like subcutaneous immunotherapy, sublingual immunotherapy is indicated for those with allergic rhinitis/conjunctivitis who have not responded to or tolerated conventional pharmacotherapy, or who are adverse to the use of these conventional treatments.

# Prevention


- synthetic fiber pillows and impermeable mattress covers
- Frequently washing bed sheets, pillowcases, and blankets in hot water
- Removing upholstered furniture, soft toys, and carpets
- Exterminating cockroaches to eliminate exposure
- Using dehumidifiers in basements and other poorly aerated, damp rooms
- Treating homes with heat-steam
- Using high-efficiency particulate air (HEPA) vacuums and filters
- Avoiding food triggers
- Limiting pets to certain rooms or keeping them out of the house
- Frequently cleaning the house
- Adjunctive nonallergenic triggers (eg, cigarette smoke, strong odors, irritating fumes, air pollution, cold temperatures, high humidity) should also be avoided or controlled when possible.

# Food allergy

- Some food antigens stimulate innate immune responses
- peanut allergen Ara h1 binds to CD209 on DCs
- milk sphingomyelin activates type 2 cytokine responses from invariant NKT cells
  
- Changes in microbial flora: associated with allergic sensitization (supporting protection by specific bacteria and their products) through sustaining intestinal Treg population
  
-



# Food allergy



The Immunology of Food Allergy  
 Laura K. Johnston,  
 Karen B. Chien and Paul J.  
 Bryce  
<http://www.jimmunol.org/content/192/6/2529> doi:  
 10.4049/jimmunol.1303026 J  
 Immunol 2014; 192:2529-2534;

maintenance of tolerance in intestine:

Through IL-10-producing Tregs and IgA-secreting B cells; performed by macrophages, CX3CR1<sup>+</sup> APCs, CD103<sup>+</sup> DCs

Critical signals for tolerance: retinoic acid (RA), IDO, and TGF-β.

Disturbance of cells or mediators

Initiating signals for sensitization - intrinsic activities of food components on innate cells (NKT), exposure to bacterial toxins, such as SEB.

Th2-response; switch to IgE

Role may play IL-33 and activation of innate lymphoid cells (ILCs).